Astex Pharmaceuticals

Astex Pharmaceuticals

UK - Cambridge
Pharmaceutical1 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Fragment-Based Drug Discovery

Astex Pharmaceuticals is a life sciences company focused on Fragment-Based Drug Discovery.

Neurology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

multitargeted receptor tyrosine kinase inhibitor MP470
Lymphoma
N/A
Clinical Trials (1)
NCT00504205MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
N/A
Phase 1
Clinical Trials (1)
NCT03922555ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
Phase 1
Phase 1
Clinical Trials (1)
NCT04479800Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT02608437A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients
Phase 1
Bisantrene Dihydrochloride
Acute Myeloid Leukemia
Phase 1
Phase 1
Clinical Trials (1)
NCT06802146Early Intervention in High Risk CCUS
Phase 1
Phase 1
Clinical Trials (1)
NCT06191978A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1
Phase 1
Clinical Trials (1)
NCT04637009A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Phase 1
Aurora kinase inhibitor AT9283
Non-Hodgkins Lymphoma
Phase 1
Clinical Trials (1)
NCT00443976Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT00894894Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
Phase 1
Oral Decitabine
Head and Neck Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT00006047Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
Phase 1
MP-470 + topotecan
Malignant Disease
Phase 1
Clinical Trials (1)
NCT00881166Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
Phase 1
Pembrolizumab
Lung Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT01966289SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Phase 1
Rubitecan
Tumors
Phase 1
Clinical Trials (1)
NCT00113113Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Phase 1
Cedazuridine
Healthy Volunteers
Phase 1
Clinical Trials (1)
NCT04953923Thorough QT Assessment of Cedazuridine in Healthy Subjects
Phase 1
Phase 1
Clinical Trials (1)
NCT05245682Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Phase 1
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT00878423Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
Phase 1
Phase 1
Clinical Trials (1)
NCT04155580A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1
Phase 1
Clinical Trials (1)
NCT04411030A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
Phase 1
Decitabine
Solid Tumor
Phase 1
Clinical Trials (1)
NCT03875287Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Phase 1
Phase 1
Phase 1
Clinical Trials (1)
NCT04466514A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
Phase 1
ASTX727 + Day 2 Food
Myelodysplastic Syndromes
Phase 1
Clinical Trials (1)
NCT03813186Effect of Food on Blood Levels of ASTX727
Phase 1
Phase 1
Clinical Trials (1)
NCT00848601Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT01239108Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
Phase 1
Decitabine and Cedazuridine
Chronic Myelomonocytic Leukemia
Phase 1/2
Clinical Trials (1)
NCT04655755Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase 1/2
CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
Acute Myeloid Leukemia
Phase 1/2
Clinical Trials (1)
NCT04013880ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Phase 1/2
pentostatin for injection
Acute Graft Versus Host Disease
Phase 1/2
Clinical Trials (1)
NCT00032773Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
Phase 1/2
Guadecitabine
MDS
Phase 1/2
Clinical Trials (1)
NCT01261312SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
Phase 1/2
ASTX727
MDS/MPN
Phase 1/2
Clinical Trials (1)
NCT04061421Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Phase 1/2
ASTX727 Dose Escalation
Myelodysplastic Syndrome
Phase 1/2
Clinical Trials (1)
NCT02103478Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT01685268A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT01183949Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT00522990Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Phase 1/2
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT01896856Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT05360160A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT01712217A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
Phase 1/2
Pentostatin
Leukemia
Phase 1/2
Clinical Trials (1)
NCT00506922Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
Phase 1/2
Phase 2
SGI-110 administration
MDS
Phase 2
Clinical Trials (1)
NCT02197676A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response
Phase 2
Phase 2
Phase 2
Clinical Trials (1)
NCT03603964Guadecitabine Extension Study
Phase 2
Phase 2
Clinical Trials (1)
NCT01145989A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
Phase 2
Phase 2
Clinical Trials (1)
NCT01752933SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Phase 2
Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 40 clinical trials
H-1B (2023): 1 approval

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 2 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub